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A B S T R A C T
In recent years the volume and complexity of flow cytometry data has increased substantially. This has led to a greater number of identifiable cell populations in a
single measurement. Consequently, new gating strategies and new approaches for cell population definition are required. Here we describe how the EuroFlow
Lymphoid Screening Tube (LST) reference data base for peripheral blood (PB) samples was designed, constructed and validated for automated gating of the distinct
lymphoid (and myeloid) subsets in PB of patients with chronic lymphoproliferative disorders (CLPD). A total of 46 healthy/reactive PB samples which fulfilled pre-
defined technical requirements, were used to construct the LST-PB reference data base. In addition, another set of 92 PB samples (corresponding to 10 healthy
subjects, 51 B-cell CLPD and 31 T/NK-cell CLPD patients), were used to validate the automated gating and cell-population labeling tools with the Infinicyt software.
An overall high performance of the LST-PB data base was observed with a median percentage of alarmed cellular events of 0.8% in 10 healthy donor samples and
of 44.4% in CLPD data files containing 49.8% (range: 1.3–96%) tumor cells. The higher percent of alarmed cellular events in every CLPD sample was due to aberrant
phenotypes (75.6% cases) and/or to abnormally increased cell counts (86.6% samples). All 18 (22%) data files that only displayed numerical alterations, corre-
sponded to T/NK-cell CLPD cases which showed a lower incidence of aberrant phenotypes (41%) vs B-cell CLPD cases (100%). Comparison between automated vs
expert-bases manual classification of normal (r2= 0.96) and tumor cell populations (rho=0.99) showed a high degree of correlation.
In summary, our results show that automated gating of cell populations based on the EuroFlow LST-PB data base provides an innovative, reliable and reproducible
tool for fast and simplified identification of normal vs pathological B and T/NK lymphocytes in PB of CLPD patients.
1. Introduction
Multiparameter flow cytometry has become the method of choice
for phenotypic characterization of normal and pathological blood and
immune cell populations, particularly in the field of hemato-oncology
(Johansson et al., 2014; Leach et al., 2013; Matarraz et al., 2017; Paiva
et al., 2016; Swerdlow et al., 2008; van Dongen et al., 2012) and pri-
mary immunodeficiencies (Blanco et al., 2019; O'Gorman et al., 2011;
van der Burg et al., 2019). This has been strongly facilitated by: i) an
increased number of phenotypic markers available to investigate blood
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and immune cells (Engel et al., 2015); ii) availability of greater num-
bers and high-quality antibody clones and fluorochrome conjugates
(Flores-Montero et al., 2019) and; iii) development of flow cytometry
instruments capable of simultaneously analyzing more fluorochromes
and greater numbers of cells at a faster rate (Chattopadhyay et al.,
2019). These advances have generated higher volumes of data that
require subsequent analysis and interpretation by experts.
In the context of hemato-oncology, such analyses, should not only
focus on the aberrant target cell populations, but also on residual normal
cells. Because of the possibility to identify tens to hundreds of cell popu-
lations in a single measurement, classical expert-guided manual gating
strategies based on the identification of each individual cell population via
bivariate dot plots (i.e. Boolean gating strategy), has become suboptimal in
routine diagnostics. The complexity of conventional gating approaches
requires a significant amount of knowledge, expertise and time for accu-
rate interpretation of the many coexisting normal and abnormal cell
phenotypes (Heel et al., 2013; Pedreira et al., 2013; Saeys et al., 2016). In
addition, such complex expert-based manual gating approach suffers from
greater levels of subjectivity and consequently higher variability. There-
fore, it would be attractive to develop automated gating strategies, that
allow accurate and reproducible identification of distinct normal and
aberrant cell populations coexisting in a sample in routine clinical flow
cytometry diagnostics (Johansson et al., 2014; Pedreira et al., 2019;
Workgroup, 2013).
In recent years, several automated gating approaches with multiple
clustering algorithms have been proposed for identification of distinct
groups of events coexisting in a sample (Chester and Maecker, 2015;
Meehan et al., 2014; O'Neill et al., 2013; Pedreira et al., 2008a, 2013;
Petrausch et al., 2006; Saeys et al., 2016). However, only a few have
addressed automated classification of such groups of events as biologically
meaningful cell populations, and none of the automated gating strategies
has been clinically validated in large patient series (Chester and Maecker,
2015; Meehan et al., 2014; O'Neill et al., 2013; Saeys et al., 2016). In order
to overcome the above limitations, EuroFlow (a scientific consortium
aiming at standardization and innovation in flow cytometry)(van Dongen
and Orfao, 2012) has developed new data bases of fully annotated flow
cytometry data files from normal and pathological samples stained with
EuroFlow screening tubes and antibody panels (Flores-Montero et al.,
2017; Pedreira et al., 2019; Theunissen et al., 2016; van der Burg et al.,
2019; van Dongen et al., 2012). Comparison of groups of events obtained
by automated gating clustering algorithms against such data bases, allows
their unequivocal classification into cell populations with a biological and/
or clinical meaning (Pedreira et al., 2019). Automated identification of the
major and minor cell populations coexisting in a flow cytometric data file,
via automated gating and labeling, emerges as an important innovative
step in standardization and simplification of flow cytometry data analysis.
Here we describe the steps required to build EuroFlow reference
data bases for automated gating and classification of individual events
contained in flow cytometric data files using peripheral blood (PB)
samples stained with the EuroFlow Lymphoid Screening Tube (LST)
panel as illustrating model. Data base construction steps consisted of: i)
staining and selection of samples to be included in the data base; ii)
evaluation of the data files corresponding to the reference samples se-
lected and; iii) validation of the data base against independent sets of
flow cytometry data files from both normal and pathological samples,
stained and measured using identical procedures and antibody panels.
2. Material and methods
2.1. Samples
A total of 211 PB samples stained with LST and measured at 5 different
EuroFlow laboratories between 2009 and 2018, were included in this
study. Of these 211 samples, 129 were obtained from healthy donors (HD)
and 82 were from patients diagnosed with chronic lymphoproliferative
disorders (CLPD): B-cell CLPD (B-CLPD), 51 samples (40 chronic
lymphocytic leukemias cases, three follicular lymphomas, two hairy cell
leukemias, five mantle cell lymphomas and one splenic marginal zone
lymphoma); and T/NK-cell CLPD (T/NK-CLPD), 31 samples (one adult T-
cell leukemia/lymphoma, four Sézary syndromes, two T-cell prolympho-
cytic leukemias, 20 T-cell large granular lymphocyte leukemias, and four
NK-cell chronic lymphoproliferative disorders). One hundred and nineteen
of these PB samples were used to build the data base (set of test samples),
while 92 were used as a validation set, consisting of PB samples from 10
HD/reactive conditions and 82 CLPD patients. The latter 92 samples in the
validation set, were randomly selected from the pool of fully characterized
and quality-controlled samples collected for validation of the EuroFlow
data base. Quality control used for these samples included: fully annotated
WHO diagnosis and both demographics and clinical and laboratory data;
staining with the full LST antibody panel; and, exclusion of fluorescence
compensation artifacts.
Reference values for the major leucocyte and lymphocyte (B-, T- and
NK-cell) populations in PB, were defined based on 187 PB samples
stained with the EuroFlow primary immunodeficiency orientation tube
(PIDOT) as described elsewhere (van der Burg et al., 2019). Of note,
LST and PIDOT share the most relevant markers to properly identify the
major leukocyte and lymphocyte cell populations and provided iden-
tical results, as confirmed in a subset of 8 samples stained in parallel
with both the PIDOT and the LST. These 187 individuals were divided
into four age groups: i)< 15 years of age (y) (n=122); ii) 15-30y
(n=25); iii) 31-50y (n=20) and;> 50y (n=20). In turn, reference
values for surface membrane immunoglobulin (smIg) κ+/smIgλ+ ratio
were taken from the literature (Szczepanski et al., 2006) and they have
been confirmed in the 46 LST-stained normal/reactive PB samples.
In all cases, samples were collected after written informed consent
had been given by each donor or their parents, according to the
Declaration of Helsinki. Samples were then processed and stained lo-
cally at each center, using EuroFlow standard operating procedures
(SOPs) for sample preparation and staining, and data acquisition
(Kalina et al., 2012) available at www.EuroFlow.org. Samples stained
with LST and/or PIDOT were measured in FACSCanto II -Becton
Dickinson Biosciences (BD), San Jose, CA- flow cytometers, calibrated
and monitored according to the EuroFlow SOP for instrument set-up
(Kalina et al., 2012), also available at www.EuroFlow.org.
The study was approved by the local ethics committees of the par-
ticipating centers.
2.2. Construction of the normal reference data base
To construct the reference LST data base of normal/reactive PB
samples (LST-PB data base), datafiles corresponding to 119 HD/reactive
PB samples stained with the EuroFlow LST antibody panel, were used.
After data acquisition, and prior to data analysis, the technical quality
of each data file was evaluated. This included the following assess-
ments: i) confirmation of inclusion of data about all informative para-
meters in each data file -e.g. forward scatter height (FSC-H) in addition
to standard scatter and fluorescence parameters-; ii) appropriate com-
pensation profiles, as described elsewhere (Kalina et al., 2012; Tung
et al., 2004); iii) expected intensity of staining for each marker (or
group of markers) per fluorochrome in pre-defined control cell popu-
lations (Supplemental Table 1); and, iv) identification of outliers (> 1.5
times interquartile ranges). All data files failing to meet one or more of
the above pre-established criteria, including outliers, were excluded
from the data base and from further processing (Fig. 1).
2.3. Data base validation
The validation data file set consisted of data files derived from flow
cytometry measurements of normal/reactive and CLPD PB samples
stained with the EuroFlow LST panel. Each normal/reactive and CLPD
data file was analyzed using the Infinicyt software (version 2.0;
Cytognos SL, Salamanca, Spain). Data analysis included the following
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steps: i) automated gating based on unsupervised clustering algorithms
where ≥10 events were required per cluster (i.e. K parameter) at a
maximum distance/dispersion within the cluster of 0.9 (i.e. S para-
meter), as previously described in detail (Fluxá Rodriguez et al., 2017);
ii) quantitative comparison of the expression profile of the different
immunophenotypic characteristics of each cluster of events obtained in
the previous step against every cell population in the reference data
base using multiparameter analysis -i.e., principal component analysis
(PCA)(Jolliffe, 2002) and canonical clustering analysis (CA)(Fujikoshi
et al., 2010)-; iii) classification (i.e. labelling) of those clusters of events,
as phenotypically identical or not to a cell population. Thus, clusters of
events that fully matched (i.e. fall within 2.5 SD) the phenotypic fea-
tures of a given (single) cell population in the reference data base were
classified as corresponding to that specific cell population. In contrast,
other clusters of events showing differences (either phenotypic differ-
ences or numerical differences) versus the distinct cell populations in
the reference data base, were automatically “alarmed” as populations to
be checked by an expert (i.e. alarmed cluster of events/cell popula-
tions).
2.4. Statistical methods
The Kolmogorov-Smirnov test was used to assess data distribution.
Outliers were identified as those values below or above 1.5 times the
interquartile range values (i.e.< 1st quartile or > 3rd quartile) for
individual scatter and fluorescence parameters. Statistical significance
of differences between two or more independent groups was evaluated
using the Mann-Whitney U or the Kruskal-Wallis tests, respectively. For
correlation studies, the Pearson's correlation analysis or the Spearman's
rho tests were used for normal and non-normal data distribution, re-
spectively. Statistical significance was set at values ≤.05. For all sta-
tistical analyses the Statistical Package for Social Sciences (SPSS) soft-
ware (version 23; IBM, Armonk, NY) was used.
3. Results
3.1. Selection of flow cytometry data files from normal/reactive PB samples
to be included in the LST-PB data base
To build the LST-PB reference database, flow cytometric data files
from 119 normal/reactive PB samples stained with the EuroFlow LST
panel, were used. Each of these data files was independently analyzed
by two experts following pre-defined sequential manual gating steps, as
illustrated in Fig. 2. Briefly, a sequence of (“Boolean”) gates was first
used to identify each cell population in individual LST-stained normal/
reactive PB samples, using a combination of their light scatter proper-
ties and/or immunophenotypic profile (Table 1 and Fig. 2A1 and A2).
Then, debris and cell doublets -i.e. events with lower forward scatter
and/or placed outside the forward scatter (FSC)-Area vs FSC-Height
plot diagonal- (Fig. 2B1 and B2), were excluded from all previously
gated cell populations. Subsequently, the major lymphocyte (sub)sets
(e.g. smIgκ+ and smIgλ+ B-cells and CD4+, CD8+, TCRγδ+ and
CD4−/CD8−/TCRγδ− T cell populations) in addition to NK-cells,
monocytes, neutrophils and eosinophils were identified, and remaining
cells showing unspecific stainings excluded from each gated leucocyte
population (Fig. 2C1 and C2). Finally, each cell population identified
was assigned to its corresponding position in a pre-defined (hier-
archical) population tree. Clusters of events displaying leukocyte-
matching light scatter properties, (after exclusion of debris and cell
doublets) and positive staining for ≥1 LST marker (e.g. CD45), but that
could not be clearly categorized as a unique specific cell population
(e.g. dendritic cells and basophils), were labeled as “Unspecified nu-
cleated cells” in the population tree.
3.2. Quality assessment of normal/reactive PB flow cytometric data files to
be included in the LST-PB data base
After all flow cytometric data files corresponding to LST-stained
normal/reactive PB samples (n=119) had been manually analyzed,
their technical quality was individually assessed (Fig. 1). Thus, 25 data
files without stored FSC-H data, that showed inappropriate fluorescence
compensation and/or displayed other technical issues, were excluded
from further data base construction steps. The remaining 94 data files
were checked for appropriate staining patterns. For this purpose, file
number vs individual parameter dot plots were used to: i) confirm all
(relevant) cell populations were present in every data file, and ii) di-
rectly compare their staining profiles for every individual marker.
Twenty additional data files were further excluded at this stage. Sub-
sequently, outlier data files (n=28), defined as those displaying
median fluorescence/scatter intensity (MFI) values lower or higher than
the 1.5 interquartile range for the corresponding positive reference cell
population (PRCP) and negative reference cell population (NRCP)
(Supplemental Table 1) were also excluded from the LST-PB data base
at this step (Fig. 1). The remaining 46 data files were merged and in-
cluded in the reference LST-PB data base. Finally, every cell population
from each PB sample was compared against the corresponding cell
populations in all other data files using CA, to confirm that the phe-
notypic profile of every cell population in each individual data file was
within 2.5 SD of the paired cell populations in the other 45 files in the
data base (Fig. 3).
Data files of normal/reactive 
PB stained with LST
n=119
Step 1: 
Inclusion of informative scatter and fluorescence 
parameters + appropriate compensation profile 
25 files excluded
Step 2:
Optimal staining patterns 
20 files excluded
Step 3: 
Exclusion of outliers for MFIs 
28 files excluded
Final LST-PB data base 
n=46 data files
Fig. 1. Schematic representation of sequential steps followed to select PB
samples (n=46/119) to be included in the LST-PB reference data base.
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3.3. Normal/reactive PB reference count values per age group
Multivariate analysis of the phenotypic characteristics of the dis-
tinct normal PB cell populations identified according to age (i.e.< 15y;
15-30y, 31-49y and≥50y) showed highly similar and overlapping
patterns of antigen expression (data not shown). However, distinct age-
group associated cell counts were observed among the 187 normal PB
samples stained with PIDOT (Table 2). Thus,< 15y controls showed
significantly (p≤ .05) higher lymphocyte (relative) counts than older
subjects (Table 2). In contrast, healthy children<15y showed lower
neutrophil (relative) counts than healthy adults> 15 years (Table 2).
Comparison of the relative cell counts with LST vs PIDOT performed in
a subset of 8 normal PB samples stained in parallel with both antibody
combinations showed no significant differences for any cell population
identified (p < .05) with a very high degree of correlation among them
(r2= 0.99; p < .001). Reference values used for smIgκ+/smIgλ+ ratio
were taken from the literature (median 1.4%, range: 0.8%–2.4%)
(Szczepanski et al., 2006) and they were further confirmed in the 46
LST-stained normal/reactive PB samples included in the reference LST-
PB data base (median 1.4%, range: 1%–2%).
Fig. 2. LST-PB data base construction: illustrating example of the Boolean gating strategy used to identify distinct populations of nucleated cells present in normal
human PB stained with LST. All different major cell populations present in the data files of normal/reactive PB samples selected to build the LST-PB data base -i.e. T-
(light blue dots), B- (dark green dots) and NK-cells (blue events) and, plasma cells (violet dots), eosinophils (pink dots), monocytes (orange events) and neutrophils
(dark violet events), as well as “unspecified nucleated cells” (dark grey events)- (panels A1 and A2) were first identified based on their distinct light scatter properties
and phenotypic profile. Subsequently, (panels B1 and B2) debris (i.e. light yellow/green events with lower FSC-A) and cell doublets (i.e. dark yellow/green events out
of the diagonal in the FSC-H vs FSC-A dot plots) were excluded from each of the gates drawn in panels A1 and A2. Then, T- and B-cells were further subclassified as
CD4+/CD8− (pink events), CD8+/CD4− (light green dots), TCRγδ+ (light blue dots) and CD4−/CD8−/TCRγδ− (violet dots) and as surface membrane (sm) Igκ+
(light violet dots) and smIgλ+ (light pink dots), respectively (panels C1 and C2). For all cell populations, events showing unspecific staining profiles were further
identified and excluded from each population. Further information about the phenotypic profile of each cell population in the LST-PB data base is shown in Table 1.
(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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3.4. Validation of the EuroFlow LST-PB reference data base
To validate the LST-PB reference data base, 92 data files from 10 HD
and 82 CLPD patients were used. For this purpose, each FCS data file
from the validation set was compared with the reference data base,
using the automated gating and classification algorithms described
above in the Material and methods section of this manuscript using
Infinicyt software. This included two sequential steps: i) clustering of
individual events; and, ii) classification of clusters of events into cell
populations.
In the clustering step, a mean of 336 (± 267) clusters (i.e. groups of
events with similar characteristics in the multidimensional space gen-
erated by all parameters evaluated) were identified, using a minimum
number of 10 events/cluster (K) with a maximum dispersion/distance
(S) of 0.9. In the classification step, all individual clusters of events
obtained per data file, were compared with each pre-defined cell po-
pulation in the reference LST-PB data base for both their phenotypic
profile -PCA and CA- and relative distribution according to age. In
normal/reactive samples from the validation set (n=10), the vast
majority of events in the data file -median of 99.2% (range
95.5%–99.7%)- were correctly classified into one of the normal cell
populations in the data base; in contrast, in the abnormal/pathological
samples, while the majority -median of 55.6% (range 1%–98.7%)- of
events were classified as belonging to the distinct normal cell popula-
tions in the reference data base, a large fraction of them -median of
44.4% (range: 1.3%–99%)- were alarmed, and required to be checked
by an expert due to phenotypic deviations (62/82; 75.6%) and/or nu-
meric alterations (71/82; 86.6%), for 82/82 (100%) alarmed CLPD
cases. Thus, 18/82 (22%) data files were alarmed based on an altered
relative distribution of ≥1 cell population, while 72/82 data files
(78%) had both phenotypic and numerical alarms for tumor cells. Of
note, a correlation (rho=0.76, p < .001) was observed between the
percentage of events alarmed (to be checked) and the actual percentage
of abnormal cells present in the sample, as identified by expert-based
(manual) analysis -median of 49.8% (range: 1.3%–96.2%)-. As ex-
pected, automated gating typically tagged the abnormal CLPD popu-
lation as “check” under a specific lymphoid cell population (i.e. B-, T- or
NK-cells) according to its specific phenotypic profile. Interestingly,
cases that only showed numerical alarms (18/82, 22%) systematically
corresponded to T/NK CLPD (18/18; 100%). In 15/82; (18.3%) sam-
ples, technical alarms were also found, as reflected by an increased
number of checks (≥5% higher than the percentage of abnormal cells
as identified by the experts). Finally, in 2/82 (2.4%) samples two ab-
normal populations were simultaneously detected, both being correctly
alarmed during automated gating. The alarmed clusters of events were
assigned either to a normal or abnormal cell population by two in-
dependent experts with a high degree of agreement on the type and
number of normal/residual as well as clonal/aberrant cells among them
(data not shown). Similarly, an overall high degree of correlation be-
tween the type and number of normal -largely represented (i.e.> 5%)
and less abundant (i.e. ≤5%)- cell populations and abnormal CLPD cell
populations was found between the proposed automated method and
conventional expert-based manual classification approaches (r2= 0.96,
p < .001; r2= 0.84, p < .001 and rho=0.99, p < .001, respec-
tively) (Fig. 4).
4. Discussion
Due to recent technical developments, data analysis in multi-
parameter flow cytometry has become increasingly complex and time
consuming. This has challenged the capability of flow cytometry ex-
perts to perform cost-effective analysis and interpretation of data files
containing information about progressively higher numbers of events,
markers and cell populations (Mair and Prlic, 2018; Perfetto et al.,
2004; Staser et al., 2018). Current expert-based conventional strategies
for processing and interpreting flow cytometry data are strongly de-
pendent on individual expertise and prone to subjectivity. With the
increase of the complexity and volume of flow cytometry data, experts
have adopted different strategies based on e.g. predefined (gating)
templates for analysis or preferential focus on one (or a few) cell po-
pulations per sample, thereby ignoring the potential relevance of other
cell populations. Some centers have chosen restricted antibody panels,
only identifying major cell populations, such as total T-, B- and, NK cells
in patients suspicious of primary immunodeficiency. The corresponding
manual analysis strategies used in individual laboratories or by in-
dividual experts are hardly reproducible, because minor deviations in
subsequent gating steps and/or the markers selected to identify a cell
population will easily generate different results (Finak et al., 2016).
This diversity in strategies emphasizes the need for simpler, less la-
borious, less time-consuming, and more reproducible gating strategies.
Automation of cell identification allows robust and reproducible
gating and has emerged as an attractive approach to overcome the
limitations of manual expert-based gating (Bandura et al., 2009;
Futamura et al., 2015; Lugli et al., 2010; Pedreira et al., 2019, 2008a,
2013; Perfetto et al., 2004). However, in virtually all automated gating
approaches described so far, the expert's input is still required, for ex-
ample, to assign groups of events to specific cell populations producing
highly variable results (Chester and Maecker, 2015; Kalina et al., 2012;
Meehan et al., 2014; O'Neill et al., 2013; Pedreira et al., 2013, 2008b;
Petrausch et al., 2006; Saeys et al., 2016). In order to overcome this
limitation, the EuroFlow consortium has designed, constructed and
validated an automated gating and classification strategy based on
combined use of i) clustering techniques to define groups of events in a
sample; and, ii) a data base comparison step, to (objectively) classify
each individual group of events in a sample against pre-defined cell
populations in a data base (matched for sample type, antibody panel,
age and/or disease condition)(Pedreira et al., 2019), as exemplified
here for the LST in normal vs CLPD samples.
Generation of standardized and high-quality data is a pre-requisite
for successful automation of gating of (all) cell populations coexisting in
a data file, as recently recognized and addressed by the EuroFlow
Consortium (Flores-Montero et al., 2017; Kalina et al., 2012; Lhermitte
et al., 2018; Nováková et al., 2017; Theunissen et al., 2016; van der
Burg et al., 2019; van Dongen et al., 2012). Successful automation of
data analysis in clinical flow cytometry requires the use of standardized
antibody panels, instrument calibration, and sample preparation, to
assure that data files from different samples, measured on different
Table 1
Distinct cell populations identified in normal/reactive reference PB samples
with LST.
Cell population Main phenotypic features
Mature B-cells SSClo, FSClo, CD45+, CD19+, CD20+, CD3−
smIgκ smIgκ+, smIgλ−
smIgλ smIgλ+, smIgκ−
T-cells SSClo, FSClo, CD45+, CD3+, CD19−
CD4 CD4+, CD8−
CD8 CD8+, CD4−
TCRγδ CD4−, CD8−, TCRγδ+
TCRγδ− (CD4−, CD8−) CD4−, CD8−, TCRγδ−
NK cells SSClo, FSClo, CD45+, CD19−, CD20−, CD3−, CD56lo/+
Circulating plasma cells SSCint, FSCint, CD38hi, CD45−/lo, CD19+
Eosinophils SSChi, FSCInt, CD45hi, other markers− (autofluorescent
in some channels)
Neutrophils SSCint/hi, FSCint/hi, CD45+, other markers−
Monocyte SSCint, FSCint, CD45+, CD4+, CD38+
Unspecified nucleated cells Light scatter properties compatible with leukocytes
and≥ 1 positive marker in the combination, but not
categorized as unique distinct cell populationa
SSC, sideward light scatter; FSC, forward light scatter; sm, surface membrane;
Ig, immunoglobulin; TCR, T cell receptor; lo, low; int, intermediate; hi, high.
a Includes basophils and/or dendritic cells for which no LST markers exist for
their positive identification.
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days, with different flow cytometers, by different technicians, will
contain highly comparable (i.e. identical) data. In addition, such stan-
dardized panels should be appropriate for identification of all potential
(normal and aberrant) cell populations in the investigated samples.
Here we used the EuroFlow LST antibody panel (van Dongen et al.,
2012) in combination with the EuroFlow instrument calibration and
sample preparation SOPs (Kalina et al., 2012) to build and validate the
EuroFlow LST-PB data base (Pedreira et al., 2019). To build the data
base, highly strict criteria were used for inclusion of data files in order
to avoid variability caused by identifiable and recognizable technical
artifacts that have a negative impact on the overall performance of this
strategy. Because of this strict selection, only a fraction (≈40%) of all
data files met the required criteria for inclusion into the data base. This
strict selection appeared to be key to assure an accurate automated
Fig. 3. Schematic representation of merged reference data files included in the LST-PB data base. Peripheral plots are classic bivariate representations of the 46 high
quality data files of LST-stained normal/reactive samples merged into the reference LST-PB data base using Infinicyt software. In turn, the central plot shows a
bidimensional summary plot of all parameters evaluated using a multivariate data analysis graphical representation -i.e. canonical analysis (CA)- available in the
Infinicyt software. Peripheral plots highlight overlapping phenotypic profiles observed for the same cell populations identified in each individual data file. Different
cell populations are color coded and represented both as colored events and their median values (colored larger circles) for all parameters displayed in each
(peripheral) conventional bidimensional dot plots. In turn, in the CA plot in the middle panel, median values for all parameters in the data file (colored circles) and
the corresponding 2.5 SD (empty lines) for each cell population in the data base, are shown in the CA multivariate analysis graphical representation. Every color
represents a different cell population of lymphoid and myeloid cells as color coded in the text inside the central plot.
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classification of cell populations via the data base. In fact, validation of
the LST-PB data base in conjunction with the automated gating and
classification procedure showed very few alarms (typically event rates
of< 1%) in normal/reactive samples. In contrast, events rates of
≈40% were associated with alarms in data files from CLPD involved
specimens. In addition to minor alarms found for a few normal cell
populations, major alarms were detected for the bulk of CLPD popu-
lations. This translated into a sensitivity of 100% with also a high
specificity (99%) for alarms ≥5% of total tumor CLPD cells. Interest-
ingly, in 2 cases, two different abnormal cell populations were si-
multaneously identified because they were separately alarmed in the
same data file, allowing diagnosis of CLPD patients with more than one
tumor cell population. This is due to the fact that automated analysis is
not specifically focused on one or a few cell populations in the sample,
but considers all cell populations present, thereby contributing to sen-
sitive identification of samples containing ≥2 distinct (related or un-
related) tumor cell populations. Thus, in the proposed automated
classification approach, iterative comparison of each cluster vs the re-
ference population is performed. Consequently, the presence of clusters
of events which do not match any normal reference cell population, is
automatically highlighted (i.e. alarmed), even if these cell populations
are not directly related to the actual reason for sample evaluation. In
fact, this automated cell classification checks for normal vs altered
phenotypes and/or normal vs altered cell numbers for any cell popu-
lation in individual data files, avoiding overlooking any abnormal cell
population, as might occur during expert-based manual analysis.
A key feature of the EuroFlow automated gating strategy used here,
relies on how reference data bases of normal cell populations are built and
on its representativeness for the biological variability that can be observed
in large sets of normal PB samples, e.g. age-related distribution of cell
populations. As discussed above, technical variability should be minimized
via standardization of all procedures involved, in such a way that the main
source of differences reflects biologic variability or actual cell alterations
due to aberrant phenotypic profiles and/or altered cell numbers vs age-
matched controls. Of note, here we confirm that the patterns of antigen
expression of normal/reactive cell populations are highly consistent in line
with previous observations (Flores-Montero et al., 2017; Szczepanski et al.,
2006; van Dongen et al., 2012). Thus, normal biologic variability is typi-
cally well represented even with relatively limited numbers of normal
samples. In contrast, even among homogeneous cohorts of PB samples
from healthy donors, leukocyte and lymphocytes counts vary significantly
with age, as previously shown by our and other groups (Blanco et al.,
2018; Comans-Bitter et al., 1997; Damasceno et al., 2019; Lucio et al.,
1999; Shearer et al., 2003; van Dongen et al., 2019; van Lochem et al.,
2004), and confirmed here also for the cell populations identified in PB
with the LST tube. Consequently, in order to increase the sensitivity of LST
to detect abnormal cell populations, the use of numerical alarms requires
prior definition of normal age-related reference ranges. Thus, for the LST-
PB, four distinct age-associated categories of “normal PB samples” were
deemed. Of note, although absolute count values were not considered
here, they might also be used to alarm for counts that are lower or higher
than normal values for each PB cell population identified with LST.
However, regardless of the differences in antibody composition between
the PIDOT and LST tubes, both share a main set of markers devote to
identify the relevant leukocyte and lymphocyte cell populations in PB,
providing identical counts for e.g. the major T-, B-, and NK-cell popula-
tions as confirmed here via parallel staining of a group of samples with
both PIDOT and LST. Altogether, these results support the use of age as-
sociated reference values for these cell populations as obtained with
PIDOT, also for LST. In addition, reference values from smIgκ/smIgλ ratio
were taken from the literature (Szczepanski et al., 2006) and confirmed in
the 46 normal/reactive PB samples stained with the LST. Collection of a
Table 2
Distribution of different cell populations in normal/reactive PB samples (n=187) used to define relative distribution reference values according to age.
Cell population Age groups All ages
< 15y 15-30y 31-49y ≥50y
n=122 n=25 n=20 n=20 n=187
Lymphocytes 43.6% 28.8%a 32.9%a 37.7%a,b,c 39.3%
(23.3%–72.5%) (15.8%–47.5%) (14.5%–43.9%) (27.4%–47.8%) (19.6%–69.1%)
T cells 32.1% 20.8%a 23.1%a 30.6%b,c 29.8%
(14.9%–53.3%) (12.5%–35.7%) (10.2%–34.7%) (17.7%–40.4%) (14.5%–50.4%)
CD4+CD8− 20.1% 13.6%a 14.2%a 17.0%b,c 17.0%
(9.6%–37.3%) (7.2%–24%) (6.6%–21.9%) (10.4%–25.6%) (8.7%–33.2%)
CD8+CD4− 9.1% 6.6%a 7.3%a 9.4%a,b 8.5%
(3.8%–17.7%) (3.6%–14.1%) (2.3%–17.3%) (2.9%–19.8%) (3.5%–17.7%)
TCRγδ+ 2.1% 1.0%a 0.8%a 1.0%a,b 1.6%
(0.3%–5.5%) (0.2%-3.5) (0.2%–3.2%) (0.1%–2.7%) (0.3%–4.5%)
CD4−/CD8−/TCRγδ− 0.3% 0.2%a 0.2%a,b 0.1%a,b 0.3%
(0.1–0.9%) (0.08%–0.6%) (0.06%–0.4%) (0.03%–0.3%) (0.07%–0.8%)
CD4/CD8 ratio 2.2 1.8a 1.8 1.8c 2.0
(0.9–4.5) (1–3.6) (0.9–3.8) (0.5–6.4) (0.5–6.4)
Mature B cells 7.2% 3.5%a 2.6%a 2.6%a 5.1%
(2.8%–15%) (1%–5.6%) (0.7%–5.7%) (1%–4.6%) (1.4%–14.5%)
NK cells 4.7% 3.3%a 5.0%b 5.0%b 4.7%
(2%–10.8%) (1.4%–8.6%) (2.3%–10.8%) (1.9%–8.7%) (2%–9.9%)
Plasma cells 0.2% 0.05%a 0.04%a,b 0.02%a,b,c 0.07%
(0.03%–0.5%) (0.02%-0.1%) (0.01%–0.08%) (0.01%–0.05%) (0.01%–0.4%)
Eosinophils 2.3% 1.6%a 2.1%a,b 1.5%a 2.1%
(0.4%–5.6%) (0.4%–3.2%) (0.4%–20.6%) (0.03%–4.3%) (0.4%–5.6%)
Neutrophils 42.1% 58.2%a 55.4%a,b 50.6%a,b 46.6%
(15%–66%) (40.5%–75.5%) (34.8%–73.7%) (37.9%–60.5%) (18.4%–67.7%)
Monocytes 8.3% 8.0% 8.7% 8.8% 8.4%
(4.5%–13%) (3.7%–11.2%) (5%–16.6%) (5.7%–12.9%) (4.7%–13%)
Results expressed as median % (5%–95% reference ranges) values. All percentages are referred to nucleated cells, after excluding debris and cell doublets.
a p < .05 vs< 15y age group.
b p < .05 vs 15-30y age group.
c p < .05 vs 31-49y age group.
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higher number of controls to define age-associated reference ranges with
the LST-PB is ongoing.
Thus, validation of the data base against a large set of normal and
CLPD data files showed that the new EuroFlow automated gating ap-
proach can satisfactorily replace manual gating strategies in routine
laboratory diagnostics. Of note, direct prospective comparison of data
from newly obtained data files, against the (normal) LST-PB data base
also highlighted (minor) technical problems occurring in a small subset
of PB data files from the validation set as reflected by a higher rate
(> 5%) of normal/residual cells being alarmed. Such increased alarm
rates were due to a larger technical variability, reduced overall sample
quality, and/or an impact of the underlaying disease on the distribution
of the other residual cell populations (data not shown). Thus, this< 5%
threshold of alarms for normal cells might be used as a criterion to
identify successful performance of the whole strategy. In such cases, the
data base acts as an “in sample” external quality check through which
staining profiles obtained in a sample are directly compared with an
“external” data base of reference “normal” properly-stained samples,
providing an innovative tool to assess also the quality of data.
A major obstacle in standardization concerns variations in both
analytical and pre-analytical steps. Among other factors, reproduci-
bility of the results strongly depends on the quality of the sample, in-
fluenced by anticoagulant, transport time and temperature during
transportation, time and temperature prior to staining and the flow
Fig. 4. Correlation between the number of total normal residual cells (panel A), including those normal residual cells present at frequencies below 5% (panel B), and
tumor cells (panel C) in PB samples from both healthy donors (n=10) and CLPD patients (n=82) evaluated either using automated gating with the LST-PB data
base or conventional expert-based manual gating.
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cytometry measurement, quality of reagents between different lots from
one manufacturer, and between reagents from different manufacturers,
reagent deterioration over time, inappropriate reagent handling and
storage conditions (Böttcher et al., 2017; O'Donnell et al., 2013). Usage
of the EuroFlow data bases also requires standardization of all pre-
analytical steps, as recently shown by Diks et al. (2019). Strict stan-
dardization and control of (all) steps involved in flow cytometric phe-
notyping, prior to data analysis, will also contribute to more
reproducible and higher quality results. The here described strategy for
data analysis, based on data base-guided automated gating provides the
basis for a real-time external quality control of all individual samples
analyzed against (multicenter) reference data bases.
In summary, our results show that automated identification of cell
populations based on the EuroFlow LST-PB data base available via the
Infinicyt software provides an innovative, reliable and reproducible
tool for the recognition of normal and pathological B and T/NK lym-
phocytes in PB in patients with CLPD, with a great contribution po-
tential for standardization of clinical flow cytometry assays within as
well as outside the EuroFlow laboratories.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jim.2019.112662.
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